5.02
0.16 (3.29%)
| Penutupan Terdahulu | 4.86 |
| Buka | 4.92 |
| Jumlah Dagangan | 2,886,452 |
| Purata Dagangan (3B) | 2,203,054 |
| Modal Pasaran | 452,804,000 |
| Harga / Pendapatan (P/E Ke hadapan) | 29.41 |
| Harga / Jualan (P/S) | 0.200 |
| Harga / Buku (P/B) | 0.400 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 12 May 2025 |
| Margin Keuntungan | -12.18% |
| Margin Operasi (TTM) | -4.02% |
| EPS Cair (TTM) | -3.03 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | -1.80% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 88.00% |
| Nisbah Semasa (MRQ) | 1.00 |
| Aliran Tunai Operasi (OCF TTM) | 262.80 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | 421.85 M |
| Pulangan Atas Aset (ROA TTM) | -1.77% |
| Pulangan Atas Ekuiti (ROE TTM) | -17.65% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Menurun | Menurun |
| Biotechnology (Global) | Menurun | Menurun | |
| Stok | Fortrea Holdings Inc. | Menurun | Menurun |
AISkor Stockmoo
| Konsensus Penganalisis | -0.5 |
| Aktiviti Orang Dalam | -3.0 |
| Volatiliti Harga | 0.5 |
| Purata Bergerak Teknikal | 0.0 |
| Osilator Teknikal | -0.5 |
| Purata | -0.70 |
|
Fortrea Holdings is a late-stage contract research organization, or CRO, that provides comprehensive Phase I through IV clinical trial management, clinical pharmacology, and patient access solutions. The company works with emerging and large biopharma, medical device, and diagnostic companies to run their clinical trials as a functional-service provider, full-service provider, and offers hybrid trials. In 2023, Fortrea was formed as an independent, publicly traded company after Labcorp spun off its clinical development business, which it acquired via its purchase of Covance in 2015 for $6.1 billion. Fortrea has 19,000 staff members across 90 countries. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Core |
| % Dimiliki oleh Orang Dalam | 0.30% |
| % Dimiliki oleh Institusi | 104.28% |
Pemilikan
| Nama | Tarikh | Syer Dipegang |
|---|---|---|
| Penn Davis Mcfarland Inc | 31 Dec 2024 | 1,106,080 |
| Julat 52 Minggu | ||
| Julat Harga Sasaran | ||
| Tinggi | 15.00 (Evercore ISI Group, 198.81%) | Pegang |
| Median | 6.50 (29.48%) | |
| Rendah | 5.00 (Barclays, -0.40%) | Jual |
| 5.00 (Goldman Sachs, -0.40%) | Pegang | |
| Purata | 8.25 (64.34%) | |
| Jumlah | 3 Pegang, 1 Jual | |
| Harga Purata @ Panggilan | 6.38 | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| Goldman Sachs | 14 May 2025 | 5.00 (-0.40%) | Pegang | 4.78 |
| 04 Mar 2025 | 11.00 (119.12%) | Pegang | 10.96 | |
| Mizuho | 14 May 2025 | 8.00 (59.36%) | Pegang | 4.78 |
| 09 Apr 2025 | 10.00 (99.20%) | Pegang | 6.45 | |
| Barclays | 13 May 2025 | 5.00 (-0.40%) | Jual | 5.00 |
| 10 Apr 2025 | 6.00 (19.52%) | Jual | 5.21 | |
| Evercore ISI Group | 04 Mar 2025 | 15.00 (198.80%) | Pegang | 10.96 |
Tiada data dalam julat masa ini.
| Tarikh | Jenis | Butiran |
|---|---|---|
| 12 May 2025 | Pengumuman | Fortrea Reports First Quarter 2025 Results |
| 12 May 2025 | Pengumuman | Fortrea Announces CEO Stepping Down |
| 01 May 2025 | Pengumuman | Fortrea Named a Leader in Everest Group’s Pharmacovigilance Operations PEAK Matrix® Assessment 2025 |
| 15 Apr 2025 | Pengumuman | Fortrea Announces Date for First Quarter 2025 Financial Results and Conference Call |
| 03 Mar 2025 | Pengumuman | Fortrea Reports Fourth Quarter and Full-Year 2024 Results; Issues Full-Year 2025 Guidance |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2025 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |